Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III and IV cutaneous melanoma
1 finding from 1 review
Time to recurrence · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to lower progression‐free survival (PFS) compared with chemotherapy alone (low certainty).
1 finding from 1 review
QoL · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether chemotherapy with TKI changes bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Average change in quality of life/satisfaction · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
Anxiety · adults with tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to first seizure ‐ stratified by epilepsy type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures
The intervention showed no clear difference in time to first seizure ‐ stratified by epilepsy type ‐ Generalised… (moderate certainty).
1 finding from 1 review